| Cat. No. |
Product Name |
Information |
| PC-38130 |
ML339
CXCR6 antagonist
|
ML 339 is a potent and selective hCXCR6 antagonist (IC50 = 140 nM), 100-fold less active at the murine CXCR6 receptor (IC50 = 18 uM). |
| PC-38129 |
CXCR6 inhibitor 81
CXCR6 inhibitor
|
CXCR6 inhibitor 81 is a potent (EC50=40 nM) and selective orally bioavailable small molecule antagonist of human CXCR6 receptor. |
| PC-35940 |
CCR1 inhibitor 19e
CCR1 inhibitor
|
CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM.. |
| PC-35854 |
BI-9667
CCR1 inhibitor
|
BI-9667 (BI9667) is a potent, selective CCR1 antagonist.. |
| PC-35832 |
CCX-354
CCR1 inhibitor
|
CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis (RA). |
| PC-35600 |
LIT-927
|
LIT-927 (LIT927) is the first selective, locally and orally active CXCL12 neutraligand with Ki of 267 nM for CXCL12-TR binding inhibition. |
| PC-35572 |
CCR6 inhibitor 35
|
CCR6 inhibitor 35 is a potent and selective CCR6 inhibitor with IC50 of 6.0 nM (hCCR6). |
| PC-35514 |
AZ084
CCR8 inhibitor
|
AZ084 (AZ-084) is a potent, selective, allosteric, orally available CCR8 antagonist with Ki of 0.9 nM. |
| PC-35358 |
BL5923
CCR1 inhibitor
|
BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively. |
| PC-35323 |
JMS-17-2
CX3CR1 inhibitor
|
JMS-17-2 is a potent and selective antagonist of CX3CR1 with IC50 of 0.32 nM, displays significant selectivity for CX3CR1 over other chemokine receptors such CXCR2, CXCR1, and CXCR4 (IC50>1 uM). |
| PC-35226 |
GW-766994
CCR3 antagonist
|
GW-766994 (GW766994) is a potent, selective, orally available CCR3 antagonist with pKi of 7.86 for inhibiting eotaxin-induced eosinophil chemotaxis in vitro assays. |
| PC-35220 |
MLN3126
CCR9 antagonist
|
MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization). |
